What is Strontium 89 Chloride
Strontium-89 ((89)Sr) chloride is a parenteral radiopharmaceutical agent. It is used as palliative therapy to relieve bone pain in patients with painful skeletal metastases.
Strontium-89 emits pure beta radiation. It differs from other therapeutic radioisotopes due to its long half-life and lack of gamma emission. Due to the long half-life and extended retention in bone (> 100 days), low doses (3—4 mCi) of strontium-89 produce effective analgesia. In clinical studies, 75—80% of patients with bone pain due to metastatic prostate cancer have significant reduction in their pain following strontium-89 administration.
The use of strontium-89 as an adjuvant to external beam radiation in patients with hormone-refractory, metastatic prostate cancer resulted in significant improvements in pain control, delayed the progression of symptoms and the onset of pain at new metastatic sites and reduced the requirement for additional palliative radiation therapy.
In addition, significant decreases in prostate-specific antigen (PSA) and alkaline phosphatase levels were noted, which may indicate that strontium-89 affects disease progression.
Indications & Dosage
- bone pain
For the palliative treatment of multiple osteoblastic bony metastasis and bone pain in patients with prostate, breast, or other cancers
- bone pain
- secondary malignancy
- bone marrow suppression
- disseminated intravascular coagulation (DIC)
- intramuscular injections
- radiation therapy
- renal impairment
- spinal cord compression
- urinary incontinence
There are no drug interactions associated with Strontium-89 Chloride products.